PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19, 2019, at 8:30 a.m. ET to discuss corporate and financial results for the year that ended Dec. 31, 2018, and recent business highlights.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international) and entering passcode 1089969. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 1089969, or by visiting the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
About Spark Therapeutics
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We have successfully applied our technology in the first gene therapy approved in both the U.S. and EU for a genetic disease, and currently have four programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
||Monique da Silva
Source: Spark Therapeutics, Inc.